Novo Nordisk creates new RNA and gene therapy unit

Novo Nordisk is establishing a new technology area for RNA and gene therapy with the aim of investigating new treatments across the company's platform.

Photo: PR/Novo Nordisk

Novo Nordisk is now seriously beginning to dedicate time and resources to finding new treatment options within RNA and gene therapies, informs Senior Vice President of Global Research Technologies at Novo Nordisk Lars Fogh Iversen in a statement on Linkedin.

The company has decided to create a new technology area to focus on RNA and gene therapy, which will be anchored in the Global Research Technologies division.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs